{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=12",
    "query": {
      "intervention": "Placebo Once Weekly",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 897,
    "total_pages": 90,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T00:46:29.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04055623",
      "title": "T-regulatory Cells in ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALS (Amyotrophic Lateral Sclerosis)"
      ],
      "interventions": [
        {
          "name": "Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monthly placebo infusions + 3 times per week placebo injections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-08-14",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055623"
    },
    {
      "nct_id": "NCT06837480",
      "title": "Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Lymphedema of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "LTU-904 Portable Laser Therapy Unit (active laser device)",
          "type": "DEVICE"
        },
        {
          "name": "LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-01-15",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Nashville, Tennessee",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06837480"
    },
    {
      "nct_id": "NCT02237196",
      "title": "Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cat Allergy",
        "Cat Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "AMG 157",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AMG 157 Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 121,
      "start_date": "2015-03-03",
      "completion_date": "2019-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237196"
    },
    {
      "nct_id": "NCT03633227",
      "title": "Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Cirrhosis, Biliary"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid (OCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 22,
      "start_date": "2018-06-22",
      "completion_date": "2021-07-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-06",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 11,
      "location_summary": "Rialto, California • Sacramento, California • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633227"
    },
    {
      "nct_id": "NCT01806597",
      "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Palmoplantar Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab 150 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "secukinumab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2013-06-19",
      "completion_date": "2016-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01806597"
    },
    {
      "nct_id": "NCT00897715",
      "title": "Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Rilonacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-01-01",
      "completion_date": "2015-05-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897715"
    },
    {
      "nct_id": "NCT03320174",
      "title": "Long-Term Safety Study of Tafenoquine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "60 Degrees Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 600,
      "start_date": "2017-10-05",
      "completion_date": "2021-07-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 2,
      "location_summary": "Colorado Springs, Colorado • McAllen, Texas",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03320174"
    },
    {
      "nct_id": "NCT02079480",
      "title": "Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986090",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with BMS-986090",
          "type": "DRUG"
        },
        {
          "name": "Keyhole limpet hemocyanin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 130,
      "start_date": "2014-05",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-05-12",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079480"
    },
    {
      "nct_id": "NCT01041274",
      "title": "DECIFER: Depression and Citalopram In First Episode Recovery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizophreniform Disorder"
      ],
      "interventions": [
        {
          "name": "Citalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Psychoeducation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Behavioral Therapy (CBT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Functional Magnetic Resonance Imaging (fMRI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "RADIATION"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 95,
      "start_date": "2010-01",
      "completion_date": "2018-03-26",
      "has_results": true,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01041274"
    },
    {
      "nct_id": "NCT00311090",
      "title": "Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Idrabiotaparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "Idraparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "Avidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Avidin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 757,
      "start_date": "2006-04",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-11-12T00:46:29.580Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00311090"
    }
  ]
}